Julien Masliah-Planchon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julien Masliah-Planchon has a total of 530 co-authors. Here are the top co-authors by number of shared publications:
- Ivan Bièche
Department of Genetics, Institut Curie, Paris, France
34 shared publications - Franck Bourdeaut
Institut Curie, Paris, France
27 shared publications - Gaelle Pierron
Genetics Department Curie Institute & PSL Research University, Paris, France
21 shared publications - Olivier Delattre
INSERM U830, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, SIREDO Oncology Center, Institut Curie Research Center, Paris, France
20 shared publications - Gudrun Schleiermacher
Institut Curie, Paris, France
18 shared publications - Maud Kamal
Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France
18 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from DNMT3B Plays Antagonistic Roles with SMARCB1 and Is a Targetable Vulnerability in Rhabdoid Tumors
Table S1 from DNMT3B Plays Antagonistic Roles with SMARCB1 and Is a Targetable Vulnerability in Rhabdoid Tumors
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from DNMT3B Plays Antagonistic Roles with SMARCB1 and Is a Targetable Vulnerability in Rhabdoid Tumors
Table S1 from DNMT3B Plays Antagonistic Roles with SMARCB1 and Is a Targetable Vulnerability in Rhabdoid Tumors
- Open Access
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
Primary tumor types (A) and biopsy sites (B).
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
Primary tumor types (A) and biopsy sites (B).
- Open Access
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
Flow chart of the study. No further treatment = clinical deterioration.
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
Flow chart of the study. No further treatment = clinical deterioration.
- Open Access
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
Study design. RAF/MEK, rapidly accelerated fibrosarcoma/mitogen-activated protein kinase kinase.
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
Study design. RAF/MEK, rapidly accelerated fibrosarcoma/mitogen-activated protein kinase kinase.
- Open Access
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
Molecular gene targets validated by MBB for n = 72 patients (A) and corresponding targeted treatments received for n = 34 patients (B).
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
Molecular gene targets validated by MBB for n = 72 patients (A) and corresponding targeted treatments received for n = 34 patients (B).
- Open Access
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
Overall survival according to the number of prior lines of systemic treatment
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
Overall survival according to the number of prior lines of systemic treatment
- Open Access
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
OS according to PFS ratio eligibility. OS was measured since inclusion (OS1).
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
OS according to PFS ratio eligibility. OS was measured since inclusion (OS1).
- Open Access
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Figure 6 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
OS according to ECOG PS. OS was measured since inclusion (OS1).
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
OS according to ECOG PS. OS was measured since inclusion (OS1).